Evidence map›Paper›PMID 9138574›Full record

ArticleBiophysical journal1997

Inhibition of cross-bridge binding to actin by caldesmon fragments in skinned skeletal muscle fibers.

J F Heubach, R Hartwell, M Ledwon, T Kraft, B Brenner, J M Chalovich

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

J F HeubachInstitute of Naturheilkunde, University Clinics Ulm, Germany.
R Hartwell
M Ledwon
T Kraft
B Brenner
J M Chalovich
Universitätsklinik für Hals-, Nasen- und Ohrenheilkunde · DE

Funding

Acting Based Regulation of Smooth Muscle ContractionR01AR035216 · NIAMS · EAST CAROLINA UNIVERSITY · PI CHALOVICH, JOSEPH M · 1986 to 2007
$1.5M
WEAKLY BOUND CROSSBRIDGES AND MUSCLE CONTRACTIONR01AR040540 · NIAMS · EAST CAROLINA UNIVERSITY · PI CHALOVICH, JOSEPH M · 1991 to 1994
–
NIAMS NIH HHS AR35216NIAMS NIH HHS AR40540-04
6 · The paper itself

Abstract

Several regions within the 35-kDa COOH-terminal portion of caldesmon have been implicated in the ability of caldesmon to inhibit actin-activated myosin ATPase activity. To further define the functional regions of caldesmon, we have studied the effects of three chymotryptic fragments, one fragment produced by CNBr digestion and two fragments produced by digestion with submaxillaris arginase C protease, on the relaxed stiffness and active force of rabbit psoas fibers. Each of the regions of caldesmon studied had either direct or indirect effects on single-fiber mechanics. The 35-kDa and 20-kDa fragments of caldesmon, like intact caldesmon, were effective inhibitors of fiber stiffness, a measure of cross-bridge attachment. The 7.3-kDa and 10-kDa fragments, which constitute the NH2 and COOH halves of the 20-kDa fragment, inhibited both relaxed fiber stiffness and active force production, but with a reduced efficacy compared to the 20-kDa fragment. These results suggest that several regions within the 35-kDa COOH-terminal region of caldesmon are required for optimum function of caldesmon and that function includes inhibition of weak cross-bridge attachment and force production.

Indexed as

ActinsAnimalsCalmodulin-Binding ProteinsIn Vitro TechniquesIsometric ContractionKineticsMolecular WeightMuscle Fibers, SkeletalMuscle, SkeletalMyosinsPeptide FragmentsRabbitsTropomyosinTroponinActinsCalmodulin-Binding ProteinsMyosinsPeptide FragmentsTropomyosinTroponin

Identifiers

PMID9138574
PMCPMC1184511
OpenAlexW2090432312

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.